{
    "2021-05-07": [
        [
            {
                "time": "",
                "original_text": "中国银河证券维持天坛生物推荐评级：业绩符合预期，看好发展前景",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "推荐评级",
                        "业绩符合预期",
                        "发展前景"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物(600161)：业绩符合预期 看好发展前景",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "业绩符合预期",
                        "发展前景"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "“四大白酒天王”操作大分化 布局有何玄机？",
                "features": {
                    "keywords": [
                        "白酒",
                        "天王",
                        "操作分化",
                        "布局"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "食品饮料"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "国信证券-天坛生物2020年报及2021一季报点评：Q1业绩略超预期，规模化优势有望进一步扩大【公司研究】",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "2020年报",
                        "2021一季报",
                        "Q1业绩略超预期",
                        "规模化优势"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "29股获券商买入评级 奥园美谷目标涨幅达75.74%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "奥园美谷",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "房地产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}